Jeff Taylor, Mphasis Digital Risk Co-Founder & Managing Partner, joined Yahoo Finance to discuss the state of housing.
Jeff Taylor, Mphasis Digital Risk Co-Founder & Managing Partner, joined Yahoo Finance to discuss the state of housing.
The chief executive of airline easyJet said Britain was likely to be left behind the rest of Europe if the government does not allow quarantine-free travel to most of the continent. Britain will on Friday announce its "green list" of low risk places where people can travel without needing to quarantine on their return home, but reports suggest that just a handful of countries will make the list, with major destinations like Spain and Greece excluded. "It's going to you know be very odd and ironic that actually the UK, the most advanced when it comes to the roll out of the vaccination programme, is actually going to find themselves left behind," easyJet Chief Executive Johan Lundgren told the FT Live online conference on Thursday.
Charles Taylor, the leading provider of insurance services, claims and technology solutions to the global insurance market, has today announced that Alison Black joins the firm this week as Chief People Officer. Alison joins Charles Taylor from AXA where she served in a range of HR leadership roles, including as Global HR Director for AXA Corporate Solutions. At Charles Taylor, Alison is responsible for leading the HR function and for driving the recruitment, development, retention, succession and reward of talent across the Group. Alison will join the Charles Taylor Executive Committee and will report to the Chief Operating Officer, Richard Yerbury.
Fishing vessels were seen moving towards the British Crown Dependency of Jersey on the morning of May 6 amid a dispute over post-Brexit fishing rights.This video shows the vessels moving northwest from the French mainland. Two Royal Navy ships, HMS Severn and HMS Tamar, were deployed to Jersey on the evening of May 5 “to conduct maritime security patrols”, the UK’s Ministry of Defence said.The BBC reported tensions between the UK and France had grown after threats were made to “blockade” Jersey with fishing vessels.As of 8 am, 24 French-flagged vessels were in the vicinity of St Helier, Jersey. Credit: MarineTraffic via Storyful
Many ‘Line of Duty’ fans were quick to speculate that ‘H’ was an allegory for the life and work of Boris Johnson. Here’s the thing, though...
Spain is moving aggressively to land new battery and electric vehicle plants, using billions of European Union pandemic relief funds to avoid being left behind as the global auto sector undertakes the biggest technology transformation in a century. As Europe's second largest car-producing nation behind Germany, and with the automotive sector accounting for 10% of its economy, Spain has a lot to lose as automakers overhaul supply chains and manufacturing for electric vehicles. Germany and number three European producer France are already pouring funds into battery plants, supporting their respective national champion automakers, and both Volkswagen and Renault are investing heavily in EVs on their home turf.
VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease (“Alzheimer’s”). Akome’s ‘next-generation’ psychedelic drug formulation, also known as AKO002, is comprised of the psychedelic compound psilocybin and a plant bioactive which, when combined together, are believed to be complementary and/or synergistic in the treatment of Alzheimer’s. A provisional matter of composition patent application for AKO002 has been filed with the United States Patent and Trademark Office (USPTO) under application number 63123838. Alzheimer’s is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. It is a progressive neurological disorder characterized by extracellular amyloid protein deposition and intracellular tau protein aggregates that, in accumulation, are associated with a variety of pathological processes including microtubular damage, axonal transport disruption and, ultimately, cell death. The hippocampus, a key structure in the ability to learn and retain information and a site for neurogenesis, is particularly vulnerable to Alzheimer’s pathology, including increased inflammation, and one of the earliest parts of the brain to be affected by the disease. Current approaches of treating Alzheimer’s focus mainly on treating symptoms of the disease, however available drugs do not change the underlying disease process. Currently there are no disease-modifying treatments for Alzheimer’s. Akome’s data analysis and mapping reveals anecdotal evidence that psychedelics have positive effects in the promotion of neuroplasticity and neurogenesis and act as agonists at serotonin receptors, including the 5HT2A receptors (5HT2A-R), that appear in high concentrations, in regions of the brain that are vulnerable to Alzheimer’s, such as the hippocampus. Additionally, psychedelics have been shown to have potent anti-inflammatory properties, and given their affinity for the 5HT2A-R, may represent a unique anti-inflammatory overwhelmingly targeted to brain tissue. Akome’s plant bioactive seems to work in a complementary way with the psilocybin compound, as it has several mechanisms of action including β-amyloid reduction and increased cerebral blood flow. Akome will continue to develop on its initial data mapping, and analysis of its bioactive-psilocybin, as it sets the process for stage two of its novel AKO002 psychedelic drug formulation and its advancement for the treatment of Alzheimer’s Disease. “Akome’s novel drug formulation for the treatment of Alzheimer’s could be a revolutionary development for the world of neurological science, and a life changer for the millions of people who are suffering from this devastating disease. We are very excited at the prospect of this drug formulation, as it reaches a relatively untapped patient base for psychedelic treatment.” stated Joel Shacker CEO of the Company. About Core One Labs Inc. Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders. Core One Labs Inc. Joel ShackerChief Executive Officer FOR MORE INFORMATION, PLEASE CONTACT: email@example.com 1-866-347-5058 Cautionary Disclaimer Statement: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.
Japan's Nintendo Co Ltd on Thursday forecast Switch console sales to reach 25.5 million units in the financial year that started April 1, signalling expectations of the hit device peaking. Nintendo sold 28.8 million Switch consoles in the year ended March 31. With Nintendo a major beneficiary of the COVID-19 pandemic-induced gaming boom, market participants are now focused on whether the Switch can maintain momentum in its fifth year of life amid speculation over new games and a hardware refresh.
Company Announcement Copenhagen, 6 May 2021 No. 15/2021 Acquisition of ISS A/S shares by Group CFO ISS A/S (ISS.CO, ISS DC, ISSDY), a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by persons discharging managerial responsibilities in ISS A/S and/or their closely associated persons. Group CFO Kasper Fangel has purchased 1,557 shares in ISS A/S (as described in attached notification) and now holds a total of 4,192 shares in the company. For investor enquiries Michael Bjergby, Head of Group Investor Relations, +45 31 37 41 71 Louisa Baruch Larsson, Senior Investor Relations Manager, +45 38 17 63 38 For media enquiries Kenni Leth, Head of Global PR & Media Relations, +45 51 71 43 68 About ISS ISS is a leading workplace experience and facility management company. In partnership with customers, ISS drives the engagement and well-being of people, minimises the impact on the environment, and protects and maintains property. ISS brings all of this to life through a unique combination of data, insight and service excellence at offices, factories, airports, hospitals and other locations across the globe. In 2020, ISS Group’s global revenue amounted to DKK 70 billion. For more information on the ISS Group, visit www.issworld.com. ISS A/S, ISIN DK0060542181, ISIN US4651472056, ISS Global A/S, ISIN XS2013618421, ISIN XS1145526825, ISIN XS1673102734, ISS Finance B.V., ISIN XS2199343513 Attachments ISS Announcement 060521 - Kasper Fangel shares PDMR reporting - Kasper Fangel
Tokyo stocks jumped Thursday after rallies on Wall Street, as investors watched corporate earnings in Japan.The benchmark Nikkei 225 index ended up 1.
Follow the latest coronavirus updates here
Improved or stable commercial performance across all main products in TDC Group as well as continued cost savings resulted in a small decline in EBITDA in Q1 (-1.8% YoY)TDC Group’s operating expenses improved by 11.5% YoY in Q1, driven by cost reductions across TDC Group, primarily in Nuuday (13.7%) Capex decreased by 27.6% YoY, driven by reduced costs following the completion of last year’s mobile network 5G-swap as well as lower activity in fibre rollout due to COVID-19Leverage for DKT Finance was 5.3x (5.3x in Dec 2020) and for TDC A/S 3.6x (3.5x in Dec 2020). Additional RCF of DKK 2.577m was raised in Q1 to secure sufficient liquidity to cash flows the next 24 months – including operations, investment programs and maturing funding in 2022TDC NET’s EBITDA totaled DKK 1,154m, increasing by 72m from Q4 2020 to Q1, however a decrease of 1.4% compared to the same period last year YoY revenue declined by 5.2%, driven by mainly fewer customer installations due to COVID-19 and continued decline on legacy productsGross profit decreased by 2.5% YoY, as the GP margin improved due mainly to growing revenues in mobility services and lower revenues from low margin productsOperating expenses decreased by 5.2% YoY in Q1, as costs related to the separation of TDC decreased as part of our focus on optimising our organisation TDC NET’s capex decreased by 26.3% YoY in Q1, driven by the YoY effect of the 5G swap as well as lower activity in fibre rollout due to COVID-19 and weather conditions - 17k homes were passed with fibre in Q1. The fibre rollout is regaining the pace and homes passed with fibre are expected to be back on a similar level to previous quarters in Q2Best mobile network TDC NET committed to invest DKK 795m in the latest spectrum auction, which will give us a strong foundation to further develop Denmark's best mobile network for consumers, businesses and institutions throughout the country. TDC NET was the only company in the auction to acquire spectrum on all five frequency bands TDC NET was awarded best mobile network in Denmark by Teknologisk Institut (Danish Technological Institute) for the 6th consecutive year. In addition, in the latest tests done by Tutela, TDC NET had the best mobile network in the Nordics Nuuday EBITDA declined by 7.0% in Q1 YoY, driven mainly by fewer RGUs in low-speed broadband and landline voice within our mature services segment. Nuuday’s revenue declined by 3.3% YoY in Q1 driven by the structural decline in mature services, e.g. landline voice, low-speed broadband and traditional TV packages.Gross profit declined by 11.4% YoY in Q1 while showing a flat development compared to Q4 2020 declining 0.3%. The mature services, primarily low-speed broadband and landline voice were also the main driver of the YoY gross profit decline. This was partly offset by a 1.1% increase in TV gross profit YoY. In Q1 YoY, Nuuday reduced operating expenses by 13.7% driven by significant reductions in personnel cost along with savings across opex categories. Capex declined by 26.2% in Q1 YoY driven by lower costs related to customer installations and lower investments in privately owned networks and IT.In Q1, Nuuday maintained its position as market leader across all products with small changes in market shares, prompted by positive trends in YouTV and Eesy following their launch in 2H 2020. Conference call details A conference call will be held on 06 May 2021 at 14:30 CET. Presentation material will be available prior to the conference call on www.tdcgroup.com Dial-in details: +45 32 72 51 67 - Meeting ID: 256 316 081# Webcast: https://teams.microsoft.com/l/meetup-join/19%3ameeting_YWM1M2I2ZDQtNzdhNC00OWQzLTg2NTgtYzcyZGQxZTdhYzhh%40thread.v2/0?context=%7b%22Tid%22%3a%22e8dcf6e6-3acc-4af9-9cb2-77f688cb688b%22%2c%22Oid%22%3a%22e3bc77b8-3126-4e3f-b136-3297ef0a91d3%22%7d For investor enquiries: +45 66 63 76 80 For media enquiries: +45 70 20 35 10 This notification is made by Klaus Rose, Treasury Analyst at TDC A/S. Attachments Release 2 -2021 Q1 TDC Q1 2021 Financial Presentation TDC_ER_Q1_2021
The former commander was demoted until the ex-president intervened
NASCAR rolled out its 'next gen' cars on Wednesday and said it's preparing for a shift to hybrid powertrains.
SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the "Company" or "SpeakEasy") a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act is excited to announce it is 4 months into a 6-9 month application process to receiving its Narcotics Dealers License ("NDL") in-order to develop and standardize psilocybin cultivation. A NDL licenced dealer may produce, assemble, sell, provide, transport, send, deliver, import or export a controlled drug (psilocybin) if they comply with the terms and conditions of their dealer's licence and any permit issued under the licence.
Onfido, the global identity verification and authentication company, today announced the results of a global study* that found 17% of consumers would rather watch paint dry than create a unique password for every online account they have. Issued by Censuswide, the study polled more than 4,000 consumers in the United States, the United Kingdom, France and Germany who have online or mobile accounts on their password habits, attitudes and more.
‘Gone should be the days when wild animals were treated as toys or props,’ PETA says
The Bloomberg New Economy Forum will move to Singapore this year, in part because of the "very concerning" conditions journalists face in China, according to comments by Bloomberg founder Michael Bloomberg reported by the Financial Times. Bloomberg, the billionaire founder of Bloomberg News and the former mayor of New York City, also cited "logistics" as a reason to hold the event in Singapore, the Financial Times reported. The inaugural forum, in 2018, was to be held in Beijing but was shifted to Singapore amid rising tensions between China and the United States.
What happens when the body you’re born with doesn’t reflect the person you are?
ADPT earnings call for the period ending March 31, 2021.
Image source: The Motley Fool. Evolent Health (NYSE: EVH)Q1 2021 Earnings CallMay 05, 2021, 6:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Evolent Health's earnings conference call for the quarter ended March 31, 2021.